Literature DB >> 31610037

Pathogen identification by shotgun metagenomics of patients with necrotizing soft-tissue infections.

C Rodriguez1,2,3, A Jary1, C Hua4, P-L Woerther1, R Bosc5, M Desroches1, E Sitterlé6, G Gricourt3, N De Prost1,2, J-M Pawlotsky1,2, O Chosidow4,7, E Sbidian4,7, J-W Decousser1.   

Abstract

BACKGROUND: Necrotizing soft-tissue infections (NSTIs) are life threatening, requiring broad-spectrum antibiotics. Their aetiological diagnosis can be limited by poor performance of cultures and administration of antibiotics before surgery.
OBJECTIVES: We aimed (i) to compare 16S-targeted metagenomics (TM) and unbiased semiquantitative panmicroorganism DNA- and RNA-based shotgun metagenomics (SM) with cultures, (ii) to identify patients who would best benefit from metagenomics approaches and (iii) to detect the microbial pathogens in surrounding non-necrotic 'healthy' tissues by SM-based methods.
METHODS: A prospective observational study was performed to assess the analytical performance of standard cultures, TM and SM on tissues from 34 patients with NSTIs. Pathogen identification obtained with these three methods was compared.
RESULTS: Thirty-four necrotic and 10 healthy tissues were collected from 34 patients. The performance of TM was inferior to that of the other methods (P < 0·05), whereas SM performed better than standard culture, although the result was not statistically significant (P = 0·08). SM was significantly more sensitive than TM for the detection of all bacteria (P = 0·02) and more sensitive than standard culture for the detection of anaerobic bacteria (P < 0·01). There was a strong correlation (r = 0·71, Spearman correlation coefficient) between the semiquantitative abundance of bacteria in the culture and the bacteria-to-human sequence ratio in SM. Low amounts of bacterial DNA were found in healthy tissues, suggesting a bacterial continuum between macroscopically 'healthy' and necrotic tissue.
CONCLUSIONS: SM showed a significantly better ability to detect a broader range of pathogens than TM and identify strict anaerobes than standard culture. Patients with diabetes with NSTIs appeared to benefit most from SM. Finally, our results suggest a bacterial continuum between macroscopically 'healthy' non-necrotic areas and necrotic tissues. What's already known about this topic? Necrotizing soft-tissue infections (NSTIs) are characterized by rapidly progressive necrosis of subcutaneous tissues and high mortality, despite surgical debridement combined with broad-spectrum antibiotics. The spectrum of potentially involved pathogens is very large, and identification is often limited by the poor performance of standard cultures, which may be impaired by previous antibiotic intake. Metagenomics-based approaches show promise for better identification of the pathogens that cause these infections, but they have not been evaluated in this medical context. What does this study add? Shotgun metagenomics (SM) showed higher sensitivity than 16S rRNA gene sequencing and a better ability than culture to detect anaerobic bacteria. As a result, a significant proportion of infections with bacteria, such as Pasteurella multocida or Clostridium perfringens, were detected only by SM. SM bacterial quantification enabled better detection of low amounts of bacterial DNA from macroscopically 'healthy' tissue, suggesting a subclinical infectious extension. What is the translational message? The high analytical performance of SM shown in this study should allow its future implementation for the diagnosis of necrotizing fasciitis, complementing or replacing routine methods. The large amount of data, including additional information on antimicrobial resistance, virulence profiles and metabolic adaptation of the pathogens, will improve microbiological documentation. Our results will improve our understanding of infectious pathophysiology in the future, leading to potentially better medical care.
© 2019 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31610037     DOI: 10.1111/bjd.18611

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  Genetic and Phenotypic Study of the Pectobacterium versatile Beta-Lactamase, the Enzyme Most Similar to the Plasmid-Encoded TEM-1.

Authors:  Guilhem Royer; Zoya Dixit; Jacques Pédron; Gautier Pierrat; Vanessa Demontant; Béatrice Berçot; Christophe Rodriguez; Marie-Anne Barny; Hervé Jacquier; Paul-Louis Woerther
Journal:  Appl Environ Microbiol       Date:  2022-05-16       Impact factor: 5.005

2.  Contribution of Clinical Metagenomics to the Diagnosis of Bone and Joint Infections.

Authors:  Camille d'Humières; Nadia Gaïa; Signara Gueye; Victoire de Lastours; Véronique Leflon-Guibout; Naouale Maataoui; Marion Duprilot; Marie Lecronier; Marc-Antoine Rousseau; Naura Gamany; François-Xavier Lescure; Olivia Senard; Laurène Deconinck; Marion Dollat; Valentina Isernia; Anne-Claire Le Hur; Marie Petitjean; Anissa Nazimoudine; Sylvie Le Gac; Solaya Chalal; Stéphanie Ferreira; Vladimir Lazarevic; Ghislaine Guigon; Gaspard Gervasi; Laurence Armand-Lefèvre; Jacques Schrenzel; Etienne Ruppé
Journal:  Front Microbiol       Date:  2022-04-21       Impact factor: 6.064

3.  Fatal Encephalitis Caused by Cristoli Virus, an Emerging Orthobunyavirus, France.

Authors:  Christophe Rodriguez; Guillaume Gricourt; Melissa Ndebi; Vanessa Demontant; Lila Poiteau; Sonia Burrel; David Boutolleau; Paul-Louis Woerther; Vincent Calvez; Sebastian Stroer; Jean-Michel Pawlotsky
Journal:  Emerg Infect Dis       Date:  2020-06       Impact factor: 6.883

4.  Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19.

Authors:  Christophe Rodriguez; Nicolas de Prost; Slim Fourati; Claudie Lamoureux; Guillaume Gricourt; Melissa N'debi; Florence Canoui-Poitrine; Isaac Désveaux; Oriane Picard; Vanessa Demontant; Elisabeth Trawinski; Raphaël Lepeule; Laure Surgers; William Vindrios; Jean-Daniel Lelièvre; Nicolas Mongardon; Olivier Langeron; José L Cohen; Armand Mekontso-Dessap; Paul-Louis Woerther; Jean-Michel Pawlotsky
Journal:  PLoS Pathog       Date:  2021-03-29       Impact factor: 6.823

5.  Case Report: Cerebral Nocardiosis Caused by Nocardia cyriacigeorgica Detected by Metagenomics in an Apparently Immunocompetent Patient.

Authors:  Virginie Courbin; Quentin Riller; Jean-Louis Amegnizin; Guillaume Gricourt; Vanessa Demontant; Vincent Fihman; Cecile Angebault; Matthieu Mahevas; Géraldine Gaube; Laëtitia Coutte; Jean-Michel Pawlotsky; Raphaël Lepeule; Christophe Rodriguez; Paul-Louis Woerther
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

6.  Prospective Comparison Between Shotgun Metagenomics and Sanger Sequencing of the 16S rRNA Gene for the Etiological Diagnosis of Infections.

Authors:  Claudie Lamoureux; Laure Surgers; Vincent Fihman; Guillaume Gricourt; Vanessa Demontant; Elisabeth Trawinski; Melissa N'Debi; Camille Gomart; Guilhem Royer; Nathalie Launay; Jeanne-Marie Le Glaunec; Charlotte Wemmert; Giulia La Martire; Geoffrey Rossi; Raphaël Lepeule; Jean-Michel Pawlotsky; Christophe Rodriguez; Paul-Louis Woerther
Journal:  Front Microbiol       Date:  2022-04-06       Impact factor: 5.640

7.  Metagenomic Sequencing and Histology on a Chronic Wound Identified Epstein-Barr Virus-Associated Lymphoma.

Authors:  Wan-Ting Yang; I Chiang; Chien-Hao Tseng; Chun Cheng; Jyun-Hong Lin; Po-Yu Liu; Yao-Ting Huang
Journal:  Evol Bioinform Online       Date:  2022-07-18       Impact factor: 2.031

8.  Fatal Measles Inclusion-Body Encephalitis in Adult with Untreated AIDS, France.

Authors:  Christophe Rodriguez; Meriadeg Ar Gouilh; Nicolas Weiss; Sébastian Stroer; Karima Mokhtari; Danielle Seilhean; Bertrand Mathon; Vanessa Demontant; Melissa N'Debi; Guillaume Gricourt; Paul-Louis Woerther; Jean-Michel Pawlotsky; Karl Stefic; Julien Marlet; Pierre-François Dequin; Antoine Guillon; Valérie Pourcher; David Boutolleau; Astrid Vabret; Sonia Burrel
Journal:  Emerg Infect Dis       Date:  2020-09       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.